Table 3.
Incidence and Remission Rates for Each Study Groupa
| (No./Total) | Roux-en-Y Gastric Bypass Surgery | Control Group 1 | Control Group 2 | |||
|---|---|---|---|---|---|---|
|
|
||||||
| Incidence, % [95% CI] | ||||||
| (No./Total) | Year 2 | Year 6 | Year 2 | Year 6 | Year 2 | Year 6 |
| Diabetes | 0 [0–0%] (0/299) | 2 [0–4%] (7/290) | 5 [1–9%] (12/255) | 17 [10–24%] (36/207) | 7 [2–12%] (14/213) | 15 [9–21%] (31/207) |
| Hypertension | 4 [1–7%] (9/234) | 16 [10–22%] (34/220) | 22 [15–29%] (49/219) | 31 [22–40%] (53/169) | 23 [14–32%] (34/147) | 33 [23–43%] (46/141) |
| Low HDL-C | 3 [0–6%] (8/246) | 5 [1–9%] (11/242) | 26 [18–34%] (57/217) | 32 [23–41%] (58/183) | 32 [24–40%] (65/201) | 38 [29–47%] (73/191) |
| High LDL-C | 3 [1–5%] (9/334) | 4 [1–7%] (13/328) | 12 [7–17%] (38/321) | 25 [18–32%] (66/265) | 18 [12–24%] (44/248) | 30 [22–38%] (71/237) |
| High Triglycerides | 2 [0–4%] (4/237) | 3 [0–6%] (8/234) | 14 [8–20%] (32/232) | 25 [17–33%] (48/194) | 22 [14–30%] (40/186) | 28 [19–37%] (50/177) |
| Remission, % [95% CI] | ||||||
| (No./Total) | Year 2 | Year 6 | Year 2 | Year 6 | Year 2 | Year 6 |
| Diabetes | 75 [63–87%] (66/88) | 62 [49–75%] (54/87) | 7 [0–14%] (6/93) | 8 [0–16%] (6/72) | 6 [0–13%] (5/88) | 6 [0–13%] (5/83) |
| Hypertension | 53 [43–63%] (90/169) | 42 [32–52%] (68/164) | 12 [5–19%] (18/152) | 18 [9–27%] (23/128) | 6 [1–11%] (9/157) | 9 [3–15%] (14/153) |
| Low HDL-C | 66 [57–75%] (108/165) | 67 [57–77%] (107/161) | 27 [18–36%] (46/170) | 34 [23–45%] (43/126) | 15 [6–24%] (17/111) | 18 [8–28%] (19/108) |
| High LDL-C | 57 [42–72%] (43/76) | 53 [38–68%] (40/75) | 17 [5–29%] (11/66) | 22 [6–38%] (10/46) | 6 [0–14%] (4/64) | 10 [0–20%] (6/61) |
| High Triglycerides | 69 [60–78%] (119/173) | 71 [62–80%] (120/168) | 29 [20–38%] (45/155) | 33 [22–44%] (38/117) | 29 [19–39%] (36/126) | 34 [23–45%] (40/119) |
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotien cholesterol.
a
95% CIs were adjusted for multiple comparisons.